-
Xinlitai Class 1 New Drug Application for Clinical Treatment of Major Depression
Time of Update: 2022-01-11
With the improvement of living standards and the increase of people's health awareness, it is expected that the market for depression will continue to expand .
-
The new domestic hypoglycemic medicine is hot! Over 50 Class 1 new drugs hit Hengrui and other 3 major tracks
Time of Update: 2021-12-07
Including compound preparations, there are currently 9 domestic GLP-1 receptor agonists approved for marketing (2 are domestically produced Class 1 new drugs).
-
Pharmaceutical companies are vying to lay out the "hyperglycemic" track, Class 1 new hypoglycemic drugs may welcome a major outbreak
Time of Update: 2021-12-06
to incomplete statistics, there are currently more than 50 domestically produced Class 1 new hypoglycemic drugs in the clinical application and above stage, 14 of which have entered the phase III clinical and above stage, concentrated in DPP-4, GLP-1
-
The new domestic hypoglycemic medicine is hot! Over 50 types of Class 1 new drugs are coming, Hengrui, Hausen, Haisco... 3 major tracks are racing
Time of Update: 2021-12-06
Including compound preparations, there are currently 9 domestic GLP-1 receptor agonists approved for marketing (2 are domestically produced Class 1 new drugs).
-
Yuandong Biomass Central Procurement Wins Bid Net Profit Soars 9 Major Class 1 New Drugs Brilliant
Time of Update: 2021-08-15
With the continuous growth of sales of its main products and the contribution of new increments from centralized procurement and bidding, the company achieved a net profit of 117 million yuan, a year-on-year increase of 36.
-
Zhongyuan Caifu implements the "four major projects" to create a first-class brand
Time of Update: 2021-08-14
Relying on site video surveillance, special vehicle Beidou navigation system, and big data summary system analysis, it truly reflects the production dynamics, timely follows up key tasks, efficiently solves on-site problems, and achieves technological acceleration .
-
12 pediatric Class 1 new drugs are eye-catching, Hengrui, etc. to grab the first three major direction Nuggets 70 billion market
Time of Update: 2021-08-13
A few days ago, the development of new pediatric drugs is frequent: China’s first child-specific expectorant spray has been approved for marketing, and clinical trials of the BC0335 particle for children’s respiratory syncytial virus infection have been suspended.
-
Hubei’s eight major actions to solve the chemical industry encircles the Yangtze River in and out
Time of Update: 2021-06-17
/> Huanggang started the rectification in 2017 to prevent domestic sewage, industrial waste water, and livestock and poultry manure from entering the river. 8 industrial enterprises have been renovated and 2 closed. The water quality
-
Kelun Class 1 new drug hits 2 billion injections, the first four major products that have been reviewed and will be approved
Time of Update: 2021-04-18
hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminal alanine Acylglutamine injection exceeds 2 billion yuan. This product
-
The latest achievements of major science and technology projects of "major new drug creation" released by the state: 9 class 1 new drugs approved
Time of Update: 2019-02-25
After the approval of the National Drug Administration, the new anticancer drug Dabusu supported by the special project will be officially launched after two months of production, providing a new immunotherapy mode for some cancer patients such as Hodgkin's lymphoma.
-
Zhongsheng Pharmaceutical Co., Ltd.: three major class 1 new drug researches are included in the "national major project"
Time of Update: 2019-01-08
Recently, Zhongsheng pharmaceutical announced that the special subjects of "phase I / II clinical research on the treatment of non-alcoholic steatohepatitis with zsp1601, a class I
-
[weekly report] chemical class 1 innovative drug, two major severe cases of double pipe
Time of Update: 2016-12-21
According to the data, the global market of IPF in 2015 was US $907 million, and the treatment of malignant tumors has always been a key area of research and development of major pharmaceutical enterprises in the world.
